Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616885 | 1.00 | TSHR (0.32) | TSHRNPSR1SLC6A3MEN1KMT2A | |
| SCHEMBL30675372 | 1.00 | TSHR (0.32) | TSHRNPSR1SLC6A3MEN1KMT2A | |
| SCHEMBL19616887 | 1.00 | TSHR (0.32) | TSHRNPSR1SLC6A3MEN1KMT2A | |
| SCHEMBL31057204 | 0.79 | PPM1D (0.32) | — | |
| SCHEMBL2887683 | 0.79 | PPM1D (0.32) | — | |
| SCHEMBL16413115 | 0.79 | GRIN2B (0.34) | MEN1KMT2A | |
| SCHEMBL16413113 | 0.79 | GRIN2B (0.34) | MEN1KMT2A | |
| SCHEMBL16419153 | 0.79 | GRIN2B (0.34) | MEN1KMT2A | |
| SCHEMBL18356076 | 0.78 | — | — | |
| SCHEMBL19617281 | 0.76 | LTA4H (0.33) | TSHRNPSR1SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2020047192-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20150344398-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
| US-20150344398-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | TSHR 3133/4885NPSR1 311/4885SLC6A3 386/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TSHR 4273/4885NPSR1 4791/4885SLC6A3 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.